major depressive disorder
Article
major depressive disorder is a recurring concept in the Astral Codex Ten archive, appearing 2 times across 2 issues between February 03, 2021 and August 20, 2021. The archive places it in contexts such as “it cannot find a categorical difference between major depressive disorder and normal low mood”; “for treating major depressive disorder”. It most often appears alongside 2020, ACT/SSC, aducanumab.
Metadata
- Category: Concepts
- Mention count: 2
- Issue count: 2
- First seen: February 03, 2021
- Last seen: August 20, 2021
Appears In
Related Pages
-
- 2020 (1 shared issues)
-
- SSC (1 shared issues)
-
- aducanumab (1 shared issues)
-
- aducanumab (1 shared issues)
-
- Aduhelm (1 shared issues)
-
- Adumbrations Of Aducanumab (1 shared issues)
-
- Al Capone (1 shared issues)
-
- Alien Planetwatchers Association (1 shared issues)
-
- Alzheimer’s (1 shared issues)
-
- Alzheimer’s Disease (1 shared issues)
-
- Alzheimers News Today (1 shared issues)
-
- America (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
People often ask: is depression the just same thing as normal sadness? Taxometrics seems to lean towards yes – it cannot find a categorical difference between major depressive disorder and normal low mood. But I’m not entirely satisfied with that answer, and dynamical systems theory offers a reason the answer might be no: depression is an attractor state in a dynamical system including normal sadness and many other variables. Normal sadness goes away after a few days or weeks; depression doesn’t.
But, this is isn’t about me or my company. This is about a much larger (but still small), much later stage biotech: Axsome Therapeutics. They have a market cap that, until 3 days ago, was hovering around $2 billion, and a drug that, until 3 days ago, looked to be approved very soon for treating major depressive disorder.
Inline links: Axsome Therapeutics
You see, Axsome thought they were in a good place, as did the stock market. Axome had a drug, bupropion-dextromethorphan, which had done well in their phase 3 trials for major depressive disorder. The next step after that is to submit the drug for approval to the FDA, which, when there are such clear indications of improvement, is usually a layup. An annoying layup, filled with lots of paperwork, but a layup.